Jonas M M
Combined Program in Gastroenterology, Children's Hospital, Boston, Massachusetts, USA.
J Pediatr Gastroenterol Nutr. 1996 Aug;23(2):93-106. doi: 10.1097/00005176-199608000-00001.
IFN-alpha has emerged as a promising treatment of chronic viral hepatitis. Although therapeutic response to IFN is far from universal, efficacy has been demonstrated; and studies combining IFN-alpha with other agents, as well as trials with new preparations of IFN-alpha, are under way. Children do not represent a large part of the identified population with chronic viral hepatitis. Yet children, by simple virtue of age, are more recently infected. In addition, longer life expectancies can be expected to be associated with greater morbidity from chronic viral hepatitis. Children seem to tolerate therapy with IFN-alpha well. Treatment of children with chronic viral hepatitis should be strongly considered, with protocols designed to ascertain specific pediatric safety and efficacy.
干扰素α已成为慢性病毒性肝炎一种有前景的治疗方法。尽管对干扰素的治疗反应远未普及，但已证实其有效性；并且将干扰素α与其他药物联合使用的研究以及干扰素α新制剂的试验正在进行中。儿童在已确诊的慢性病毒性肝炎患者群体中所占比例不大。然而，仅因年龄因素，儿童是较近期感染的。此外，预期寿命延长可能会伴随慢性病毒性肝炎更高的发病率。儿童似乎对干扰素α治疗耐受性良好。应强烈考虑对慢性病毒性肝炎儿童进行治疗，并制定旨在确定特定儿科安全性和有效性的方案。
